$XYL 8-K earnings — Q2 FY26

Xylem beat adjusted EPS consensus by $0.08 (5.8%) at $1.46, but revenue of $2.3B missed estimates as organic growth slowed to just 1%. The company raised full-year adjusted EPS guidance to $5.55-$5.70 from $5.35-$5.60, signaling confidence in margins despite trimming revenue outlook to ~$9.2B. The key nuance: the 42% orders surge (41% organic) dramatically outpaced revenue, suggesting a massive backlog build that hasn't converted to sales yet—investors should watch for future revenue catch-up rather than demand weakness.

Xylem beat adjusted EPS consensus by $0.08 (5.8%) at $1.46, but revenue of $2.3B missed estimates as organic growth slowed to just 1%. The company raised full-year adjusted EPS guidance to $5.55-$5.70 from $5.35-$5.60, signaling confidence in margins despite trimming revenue outlook to ~$9.2B. The key nuance: the 42% orders surge (41% organic) dramatically outpaced revenue, suggesting a massive backlog build that hasn't converted to sales yet—investors should watch for future revenue catch-up rather than demand weakness.